• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Lineage Reports First Quarter 2021 Financial Results and Highlights Significant Progress With All Three Clinical Programs

    5/13/21 4:05:00 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LCTX alert in real time by email
    • OpRegen® Clinical Data Continued to Demonstrate Improvements in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
    • Worldwide License Agreement Secured for a Cancer Immunotherapy Candidate Based on the Lineage VAC Platform
    • Exclusive Agreement Secured to Evaluate a Novel System for Enhanced Delivery of OPC1
    • Board of Directors Enhanced with Appointments of Healthcare Leaders, Drs. Anula Jayasuriya and Dipti Amin
    • Current Cash and Marketable Securities Expected to Support Operations Well Into 2023

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the first quarter 2021. Lineage will host a conference call today at 4:30 p.m. Eastern Time to discuss its first quarter 2021 financial results and to provide a business update.

    "Lineage reported significant operational progress with each of its three clinical programs during the first quarter and beyond, delivering not only continued positive clinical results with OpRegen for the treatment of dry-AMD with GA, but also validating partnerships to support our OPC1 and VAC programs," stated Brian M. Culley, Lineage CEO. "We remain encouraged by the totality of the OpRegen clinical data presented to date, which is suggestive of clinically meaningful benefits, especially in earlier stage disease dry-AMD patients. Moreover, the strategic collaborations we announced for OPC1 and VAC reflect our commitment to a comprehensive asset management approach and add external validation to the potential of our platform to create positive outcomes for patients. Additionally, the capital we brought in during the first quarter ensures that we not only are well funded to reach additional milestones, but also provide us with optionality with respect to partnership discussions."

    Some of the significant events and milestones achieved to date this year include:

    - Presented a positive interim clinical update from the ongoing Phase 1/2a study of OpRegen for the treatment of dry-AMD with GA at the 2021 Association for Research in Vision and Ophthalmology Meeting: 83% of all Cohort 4 patients exhibited stable or improved Best Corrected Visual Acuity (BCVA) while visual acuity declined in the majority of untreated eyes;

    - Reported that the first known finding of retinal tissue restoration in a patient who received a retinal pigment epithelium (RPE) cell transplant continues to demonstrate areas of retinal restoration as of their last assessment, approximately 3 years after treatment;

    - Treated a vitelliform maculopathy patient with OpRegen under named patient compassionate use: the delivery of OpRegen RPE cells via pars plana vitrectomy (PPV) was successful, with no complications arising during the procedure and the patient remains in follow-up;

    - Entered into a worldwide license agreement with Immunomic Therapeutics for an allogeneic cell-based cancer immunotherapy based on Lineage's VAC platform with a total of $2 million in upfront payments anticipated in the first year and the potential for $67 million in development and commercial milestones;

    - Entered into an exclusive agreement with Neurgain Technologies to evaluate a novel delivery system for OPC1 for treatment of spinal cord injury;

    - Announced the appointment of Anula Jayasuriya, M.D., Ph.D., M.B.A., a successful healthcare private equity executive and venture capitalist with extensive clinical, industry, entrepreneurial, and investment experience, to the Company's Board of Directors; and

    - Announced the appointment of Dr. Dipti Amin, MBBS, a medically trained senior executive with broad expertise in medicine, pharmacology, healthcare, research, and product development, to the Company's Board of Directors.

    Some of the events and milestones to look forward to during the remainder of 2021 include:

    - OpRegen Program

    • Presentation of additional interim data from the Phase 1/2a study, anticipated during the second quarter of 2021;
    • Meeting with the U.S. Food and Drug Administration (FDA) to discuss further clinical development, anticipated in the third quarter of 2021.

    - OPC1 Program

    • FDA Regenerative Medicine Advanced Therapy interaction to assess plans to evaluate the Neurgain Parenchymal Spinal Delivery (PSD) system, scheduled in June 2021;
    • Evaluation of the Neurgain PSD system;
    • Completion of improved manufacturing process, GMP production, and comparability testing to support a late-stage clinical trial;
    • FDA interaction to discuss manufacturing improvements, anticipated around the end of 2021.

    - VAC Program

    • Completion of enrollment in the ongoing VAC2 Phase 1 non-small cell lung cancer study, anticipated in mid 2021;
    • Introduction of manufacturing enhancements to the VAC platform;
    • Reporting of results from the ongoing VAC2 Phase 1 study, anticipated in the fourth quarter of 2021;
    • Evaluation of opportunities for new VAC product candidates based on internally-identified or partnered tumor antigens.

    - Continued evaluation of partnership opportunities and expansion of existing external collaborations and identification of new collaborations.

    Balance Sheet Highlights

    Cash, cash equivalents and marketable securities totaled $62.4 million as of March 31, 2021. Marketable securities of $6.2 million as of March 31, 2021 include our remaining ownership of 1,122,401 shares of common stock in OncoCyte and 169,167 shares of common stock in Hadasit Bio-Holdings Ltd.

    We added to our cash position in the first quarter of 2021 with net proceeds of $19.3 million received from sales of our common shares under our ATM offering and net proceeds of $10.1 million received from selling a portion of our marketable securities.

    No sales were conducted under our ATM offering from March 6, 2021 through May 12, 2021.

    First Quarter Operating Results

    Revenues: Lineage's revenue is generated primarily from research grants, royalties, and licensing fees. Total revenues for the three months ended March 31, 2021 were approximately $0.4 million, a decrease of $0.1 million as compared to $0.5 million for the same period in 2020. The decrease was primarily related to an approximate $0.2 million decrease in grant income, which was primarily driven by the completion of SBIR grant-related activities, offset by a $0.1 million increase in royalty-related revenues.

    Operating Expenses: Operating expenses are comprised of research and development (R&D) expenses and general and administrative (G&A) expenses. Total operating expenses for the three months ended March 31, 2021 were $7.3 million, a decrease of $0.6 million as compared to $7.9 million for the same period in 2020.

    R&D Expenses: R&D expenses for the three months ended March 31, 2021 were $3.4 million, an increase of approximately $0.1 million as compared to $3.3 million for the same period in 2020. The overall increase was primarily related to increases of $0.5 million and $0.4 million in VAC and OPC1 program expenses, respectively, and a net decrease of $0.8 million in OpRegen and other ophthalmic application expenses, primarily driven by fluctuations in the timing of manufacturing activities.

    G&A Expenses: G&A expenses for the three months ended March 31, 2021 were $3.9 million, a decrease of approximately $0.6 million as compared to $4.5 million for the same period in 2020. The decrease was primarily attributable to decreases of $0.4 million in expenses related to our merger with Asterias Biotherapeutics, Inc., $0.2 million in rent expense and utilities, $0.1 million in legal and patent expenses, and $0.1 million in compensation expense, offset by a $0.2 million increase in investor and public relations expenses.

    Loss from Operations: Loss from operations for the three months ended March 31, 2021 was approximately $7.0 million, a decrease of $0.4 million as compared to $7.4 million for the same period in 2020.

    Other Income/(Expenses), Net: Other income/(expenses), net for the three months ended March 31, 2021 reflected other income, net of $5.6 million, compared to other expense, net of ($1.0) million for the same period in 2020. The variance was primarily related to the gain on sale of marketable securities and changes in the value of marketable equity securities for the applicable periods, as well as exchange rate fluctuations related to Lineage's international subsidiaries. The increase in the value of Lineage's OncoCyte shares and subsequent sales during the first quarter 2021 contributed significantly to the overall net increase in other income.

    Net loss attributable to Lineage: The net loss attributable to Lineage for the three months ended March 31, 2021 was $1.4 million, or $0.01 per share (basic and diluted), compared to a net loss attributable to Lineage of $8.4 million, or $0.06 per share (basic and diluted), for the same period in 2020.

    Conference Call and Webcast

    Lineage will host a conference call and webcast today, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2021 financial results and to provide a business update. Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere outside the U.S. and Canada and should request the "Lineage Cell Therapeutics Call". A live webcast of the conference call will be available online in the Investors section of Lineage's website. A replay of the webcast will be available on Lineage's website for 30 days and a telephone replay will be available through May 21, 2021, by dialing (855) 859-2056 from the U.S. and Canada and (404) 537-3406 from elsewhere outside the U.S. and Canada and entering conference ID number 4996965.

    About Lineage Cell Therapeutics, Inc.

    Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage's three allogeneic ("off-the-shelf") clinical programs are in markets with billion dollar opportunities: (i) OpRegen®, an investigational retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an investigational oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, with investigational immunotherapy VAC2 currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

    Forward-Looking Statements

    Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," project," "target," "tend to," "look forward to" or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to Lineage's anticipated funding runway, data presentations, clinical trial advancement, meetings and interactions with the FDA, evaluation of the Neurgain PSD system, manufacturing improvements, enrollment in the VAC2 Phase 1 study, announcement of clinical study results, payments under the license agreement with Immunomic Therapeutics, partnership evaluations and opportunities, and market opportunity and potential for its product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage's business and other risks in Lineage's filings with the Securities and Exchange Commission (the SEC). Lineage's forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading "Risk Factors" in Lineage's periodic reports with the SEC, including Lineage's most recent Annual Report on Form 10-K filed with the SEC and Quarterly Report on Form 10-Q and its other reports, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

    LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (IN THOUSANDS)

     

     

    March 31,

    2021

    (Unaudited)

     

    December 31,

    2020

     

    ASSETS

     

     

     

     

     

     

    CURRENT ASSETS

     

     

     

     

     

     

    Cash and cash equivalents

    $

    56,210

     

    $

    32,585

     

    Marketable equity securities

     

    6,154

     

     

    8,977

     

    Trade accounts and grants receivable, net

     

    109

     

     

    4

     

    Prepaid expenses and other current assets

     

    2,149

     

     

    2,433

     

    Total current assets

     

    64,622

     

     

    43,999

     

     

     

     

     

     

     

     

    NONCURRENT ASSETS

     

     

     

     

     

     

    Property and equipment, net

     

    5,114

     

     

    5,630

     

    Deposits and other long-term assets

     

    601

     

     

    616

     

    Goodwill

     

    10,672

     

     

    10,672

     

    Intangible assets, net

     

    46,919

     

     

    47,032

     

    TOTAL ASSETS

    $

    127,928

     

    $

    107,949

     

     

     

     

     

     

     

     

    LIABILITIES AND SHAREHOLDERS' EQUITY

     

     

     

     

     

     

    CURRENT LIABILITIES

     

     

     

     

     

     

    Accounts payable and accrued liabilities

    $

    5,733

     

    $

    6,813

     

    Financing lease and right of use lease liabilities, current portion

     

    786

     

     

    762

     

    Deferred revenues

     

    101

     

     

    193

     

    Liability classified warrants, current portion

     

    1

     

     

    1

     

    Total current liabilities

     

    6,621

     

     

    7,769

     

     

     

     

     

     

     

     

    LONG-TERM LIABILITIES

     

     

     

     

     

     

    Deferred tax liability

     

    2,076

     

     

    2,076

     

    Right-of-use lease liability, net of current portion

     

    2,217

     

     

    2,514

     

    Financing lease, net of current portion

     

    26

     

     

    26

     

    Liability classified warrants, net of current portion

     

    418

     

     

    437

     

    TOTAL LIABILITIES

     

    11,358

     

     

    12,822

     

     

     

     

     

     

     

     

    Commitments and contingencies

     

     

     

     

     

     

     

    SHAREHOLDERS' EQUITY

     

     

     

     

     

     

    Preferred shares, no par value, authorized 2,000 shares; none issued and outstanding as of March 31, 2021 and December 31, 2020

     

    -

     

     

    -

     

    Common shares, no par value, 250,000 shares authorized; 162,067 and 153,096 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively

     

    415,259

     

     

    393,944

     

    Accumulated other comprehensive loss

     

    (2,091

    )

     

    (3,667

    )

    Accumulated deficit

     

    (295,494

    )

     

    (294,078

    )

    Lineage Cell Therapeutics, Inc. shareholders' equity

     

    117,674

     

     

    96,199

     

    Noncontrolling interest (deficit)

     

    (1,104

    )

     

    (1,072

    )

    Total shareholders' equity

     

    116,570

     

     

    95,127

     

    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

    $

    127,928

     

    $

    107,949

     

    LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (IN THOUSANDS, EXCEPT PER SHARE DATA)

    (UNAUDITED)

     

     

     

     

     

    Three Months Ended

    March 31,

     

    2021

     

    2020

    REVENUES:

     

     

     

     

     

    Grant revenue

    $

    98

     

    $

    348

     

    Royalties from product sales and license fees

     

    293

     

     

    166

     

    Total revenues

     

    391

     

     

    514

     

     

     

     

     

     

     

    Cost of sales

     

    (112

    )

     

    (94

    )

     

     

     

     

     

     

    Gross profit

     

    279

     

     

    420

     

     

     

     

     

     

     

    OPERATING EXPENSES:

     

     

     

     

     

    Research and development

     

    3,394

     

     

    3,339

     

    General and administrative

     

    3,935

     

     

    4,519

     

    Total operating expenses

     

    7,329

     

     

    7,858

     

    Loss from operations

     

    (7,050

    )

     

    (7,438

    )

    OTHER INCOME/(EXPENSES):

     

     

     

     

     

    Interest income, net

     

    2

     

     

    405

     

    Gain on sale of marketable securities

     

    6,024

     

     

    1,258

     

    Unrealized gain (loss) on marketable equity securities

     

    1,239

     

    (1,338

    )

    Unrealized gain on warrant liability

     

    18

     

     

    35

     

    Other expenses, net

     

    (1,681

    )

     

    (1,350

    )

    Total other income (expenses), net

     

    5,602

     

    (990

    )

    LOSS BEFORE INCOME TAXES

     

    (1,448

    )

     

    (8,428

    )

     

     

     

     

     

     

    Deferred income tax benefit

     

    -

     

     

    -

     

     

     

     

     

     

     

    NET LOSS

     

    (1,448

    )

     

    (8,428

    )

     

    Net loss attributable to noncontrolling interest

     

    32

     

     

    29

     

     

     

     

     

     

    NET LOSS ATTRIBUTABLE TO LINEAGE CELL THERAPEUTICS, INC.

    $

    (1,416

    )

    $

    (8,399

    )

     

     

     

     

     

     

    NET LOSS PER COMMON SHARE:

     

     

     

     

     

    BASIC

    $

    (0.01

    )

    $

    (0.06

    )

    DILUTED

    $

    (0.01

    )

    $

    (0.06

    )

     

     

     

     

     

     

    WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:

     

     

     

     

     

    BASIC

     

    158,725

     

     

    149,807

     

    DILUTED

     

    158,725

     

     

    149,807

     

    LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (IN THOUSANDS)

    (UNAUDITED)

     

     

     

     

     

     

    Three Months Ended

    March 31,

     

     

    2021

     

    2020

     

    CASH FLOWS FROM OPERATING ACTIVITIES:

     

     

     

     

     

     

    Net loss attributable to Lineage Cell Therapeutics, Inc.

    $

    (1,416

    )

    $

    (8,399

    )

    Net loss allocable to noncontrolling interest

     

    (32

    )

     

    (29

    )

    Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc. to net cash used in operating activities:

     

     

     

     

     

     

    Gain on sale of marketable securities

     

    (6,024

    )

     

    (1,258

    )

    Unrealized (gain)/loss on marketable equity securities

     

    (1,239

    )

     

    1,338

     

    Depreciation expense, including amortization of leasehold improvements

     

    174

     

     

    212

     

    Amortization of right-of-use asset

     

    10

     

     

    9

     

    Amortization of intangible assets

     

    112

     

     

    498

     

    Stock-based compensation

     

    539

     

     

    626

     

    Common stock issued for services

     

    102

     

     

    -

     

    Change in unrealized gain on warrant liability

     

    (18

    )

     

    (35

    )

    Foreign currency remeasurement and other gain

     

    1,712

     

    1,424

    Changes in operating assets and liabilities:

     

     

     

     

     

     

    Accounts and grants receivable, net

     

    (135

    )

     

    66

     

    Accrued interest receivable

     

    -

     

    (378

    )

    Receivables from OncoCyte and AgeX, net of payables

     

    -

     

     

    (40)

     

    Prepaid expenses and other current assets

     

    (92

    )

     

    911

    Accounts payable and accrued liabilities

     

    (1,031

    )

     

    (138

    )

    Deferred revenue and other liabilities

     

    (86

    )

     

    167

     

    Net cash used in operating activities

     

    (7,424

    )

     

    (5,026

    )

     

     

     

     

     

     

     

    CASH FLOWS FROM INVESTING ACTIVITIES:

     

     

     

     

     

     

    Proceeds from the sale of OncoCyte common shares

     

    10,064

     

     

    4,963

     

    Proceeds from the sale of AgeX common shares

     

    -

     

     

    258

     

    Proceeds from the sale of Hadasit common shares

     

    21

     

     

    -

     

    Purchase of equipment and other assets

     

    (11

    )

     

    (10

    )

    Other deposits

     

    -

     

     

    45

    Net cash provided by investing activities

     

    10,074

     

     

    5,256

     

     

     

     

     

     

     

     

    CASH FLOWS FROM FINANCING ACTIVITIES:

     

     

     

     

     

     

    Proceeds from employee options exercised

     

    1,717

     

     

    -

     

    Common shares received and retired for employee taxes paid

     

    (13

    )

     

    (2

    )

    Repayment of financing lease liabilities

     

    -

     

     

    (8

    )

    Proceeds from sale of common shares

     

    19,873

     

    -

     

    Payments for offering costs

     

    (614

    )

     

    -

     

    Net cash provided by (used in) financing activities

     

    20,963

     

     

    (10)

     

    Effect of exchange rate changes on cash, cash equivalents and restricted cash

     

    (80

    )

     

    73

     

    NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

     

    23,533

     

     

    293

    CASH, CASH EQUIVALENTS AND RESTRICTED CASH:

     

     

     

     

     

     

    At beginning of the period

     

    33,183

     

     

    10,096

     

    At end of the period

    $

    56,716

     

    $

    10,389

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005753/en/

    Get the next $LCTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LCTX

    DatePrice TargetRatingAnalyst
    8/20/2024$4.00Buy
    Craig Hallum
    11/2/2022$5.00Outperform
    Robert W. Baird
    6/14/2022$4.00Buy
    B. Riley Securities
    8/19/2021$8.00Outperform
    Noble Capital Markets
    More analyst ratings

    $LCTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on May 13, 2025, by dialing (800) 7

      5/1/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

      Fully Virtual Event Scheduled for June 27, 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation, a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by paralysis, are proud to collaborate and present the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). This year's event aims to bring together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advoc

      4/22/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

      Lineage Participating in Panel Discussion of Novel Retina Drug Delivery Approaches at Eyecelerator@ Park City 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive Officer, has been invited to join presenters from REGENXBIO Inc., Regenerative Patch Technologies, LLC, Neurotech Pharmaceuticals, Inc., and others, as part of the "I Shall Be Released: Novel Drug Delivery Approaches for Glaucoma and Retina" panel at Eyecelerator@ Park City 2025. The panel will take place on Friday, May 2, 2025 from 12:30pm to 1:30pm M

      4/21/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Leadership Updates

    Live Leadership Updates

    See more

    $LCTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

      Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical   Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"). The 2nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived exp

      5/21/24 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

      4/1/24 8:00:00 AM ET
      $LCTX
      $SYBX
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lineage Announces Appointment of General Counsel

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has appointed George A. Samuel III as Lineage's General Counsel and Corporate Secretary. Mr. Samuel will lead the Company's legal operations, bringing extensive corporate, transactional, intellectual property and commercial expertise which spans nearly 15 years across the life sciences and technology sectors as well as in private practice. "We are pleased to welcome George to our leadership team and look forward to his contributions as we build Lineage into a leading cell therapy and cell transplant comp

      9/1/21 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Broadwood Partners, L.P. bought $6,000,000 worth of shares (7,894,737 units at $0.76) (SEC Form 4)

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      1/28/25 7:49:41 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Howe Jill Ann bought $8,850 worth of shares (15,000 units at $0.59), increasing direct ownership by 143% to 25,500 units (SEC Form 4)

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      11/26/24 4:58:31 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • General Counsel Samuel George A. Iii bought $9,000 worth of shares (15,000 units at $0.60), increasing direct ownership by 209% to 22,184 units (SEC Form 4)

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      11/26/24 4:55:46 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Financials

    Live finance-specific insights

    See more
    • Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on May 13, 2025, by dialing (800) 7

      5/1/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Monday, March 10, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2024 financial and operating results and to provide a business update. Interested parties may access the conference call on Monday, March 10, 2025, by di

      3/5/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

      OpRegen® Granted Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA ReSonance™ (ANP1) Preclinical Results Presented at 59th Annual Inner Ear Biology Workshop Added to 2024 Russell 3000® Index Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. "We were delighted to see our partners' continued commitment to the OpRegen program, in this instance by seeking

      11/14/24 4:01:00 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Lineage Cell Therapeutics with a new price target

      Craig Hallum initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00

      8/20/24 8:32:59 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Lineage Cell Therapeutics with a new price target

      Robert W. Baird initiated coverage of Lineage Cell Therapeutics with a rating of Outperform and set a new price target of $5.00

      11/2/22 6:28:33 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B. Riley Securities initiated coverage on Lineage Cell Therapeutics with a new price target

      B. Riley Securities initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00

      6/14/22 7:59:45 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    SEC Filings

    See more

    $LCTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $LCTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lineage Cell Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

      5/1/25 9:09:09 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Lineage Cell Therapeutics Inc.

      DEFA14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

      4/29/25 4:10:04 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Lineage Cell Therapeutics Inc.

      DEF 14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

      4/29/25 4:05:15 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc.

      SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

      11/21/24 8:05:56 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc. (Amendment)

      SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

      2/8/24 6:57:07 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc. (Amendment)

      SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

      3/25/22 5:23:02 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President and CEO Culley Brian M

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      3/12/25 5:30:54 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Howe Jill Ann

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      3/12/25 5:30:36 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by General Counsel and Secretary Samuel George A. Iii

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      3/12/25 5:30:11 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care